NCT04098432 - STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions

Locally Advanced Unresectable Pancreatic Adenocarcinoma

Interventions

DRUG

Nivolumab

Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity

RADIATION

Stereotactic radiotherapy

The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).

Trial Locations (4)

Onkologická klinika, Thomayerova nemocnice, Prague

Ústav radiační onkologie, Nemocnice Na Bulovce, Prague

Klinika Onkologie a radioterapie, Fakultní nemocnice Hradec Králové, Hradec Králové

Onkologická klinika, Fakultní nemocnice Olomouc, Olomouc